# Varicella-Zoster Virus and the Eye: Clinical Spectrum, Management, and Vaccination

**Authors:** Wendong Gu, Yaru Zou, Mingming Yang, Jing Zhang, Zizhen Ye, Jiaxin Deng, Yuan Zong, Kyoko Ohno-Matsui, Koju Kamoi

PMC · DOI: 10.3390/pathogens15020157 · Pathogens · 2026-02-02

## TL;DR

This paper reviews how the varicella-zoster virus affects the eye, its management, and how vaccination helps reduce complications.

## Contribution

The paper synthesizes current knowledge on host-pathogen interactions in varicella-zoster virus ocular disease.

## Key findings

- VZV can cause a wide range of eye conditions, from corneal ulcers to retinal necrosis.
- PCR-based diagnostics are crucial for detecting VZV in cases without skin symptoms.
- Vaccination has reduced VZV incidence and ocular complications in high-coverage regions.

## Abstract

Varicella-Zoster Virus (VZV) is one of the most important pathogens in ophthalmology. Reactivation may involve the adnexa (blepharoconjunctivitis, pseudomembranous conjunctivitis), cornea (dendritic keratitis, nummular and necrotizing stromal keratitis, disciform endotheliitis, neurotrophic ulcers, mucous-plaque keratitis) and sclera (episcleritis, anterior scleritis). Uveal inflammation ranges from anterior uveitis—with iris atrophy, trabeculitis-induced glaucoma and complicated cataract—to posterior necrotizing syndromes: acute retinal necrosis in immunocompetent hosts and progressive outer retinal necrosis in immunosuppressed patients, often complicated by occlusive vasculitis, macular edema, retinal detachment and phthisis. Optic nerve and cranial nerve involvement (optic neuritis, neuroretinitis, III/IV/VI palsies) and orbital inflammation may occur even without cutaneous signs (“zoster sine herpete”), making PCR-based intraocular diagnostics essential. Management relies on early, high-dose antivirals (acyclovir or valacyclovir), judicious corticosteroids and timely surgical intervention when required. Universal childhood varicella vaccination and recombinant zoster vaccination in adults ≥50 years have reduced VZV incidence and ocular complications in settings with high vaccine coverage, though rare post-vaccine keratitis or uveitis underscore the need for ongoing vigilance. In this review, we synthesize current knowledge on varicella-zoster virus ocular disease, with a focus on host–pathogen interactions that drive both injury and defense.

## Linked entities

- **Chemicals:** acyclovir (PubChem CID 135398513), valacyclovir (PubChem CID 135398742)
- **Diseases:** blepharoconjunctivitis (MONDO:0002307), dendritic keratitis (MONDO:0015288), glaucoma (MONDO:0005041), cataract (MONDO:0005129), macular edema (MONDO:0003005), retinal detachment (MONDO:0008375)

## Full-text entities

- **Genes:** PLXNA2 (plexin A2) [NCBI Gene 5362] {aka OCT, PLXN2}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, LAT (linker for activation of T cells) [NCBI Gene 27040] {aka IMD52, LAT1, pp36}, GGH (gamma-glutamyl hydrolase) [NCBI Gene 8836] {aka GATD10, GH}, MMP3 (matrix metallopeptidase 3) [NCBI Gene 4314] {aka CHDS6, MMP-3, SL-1, STMY, STMY1, STR1}, GNAI1 (G protein subunit alpha i1) [NCBI Gene 2770] {aka Gi, HG1B, NEDHISB}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, IRF3 (interferon regulatory factor 3) [NCBI Gene 3661] {aka IIAE7}, TIMP1 (TIMP metallopeptidase inhibitor 1) [NCBI Gene 7076] {aka CLGI, EPA, EPO, HCI, TIMP, TIMP-1}
- **Diseases:** inflammatory myositis (MESH:D009220), Uveitis (MESH:D014605), Ocular injury (MESH:D005131), adnexal and conjunctival disease (MESH:D003229), hyperemia (MESH:D006940), Third-nerve palsy (MESH:D015840), Immune-Mediated Choroidopathy (MESH:C567355), postherpetic neuralgia (MESH:D051474), cutaneous rash (MESH:D005076), stromal opacities (MESH:D003318), VZV disease (MESH:D000073618), corneal edema (MESH:D015715), CMV (MESH:D003586), intraretinal hemorrhage (MESH:D006470), photoreceptor damage (MESH:D020263), posterior synechiae (MESH:D006175), Cranial Nerve Palsies (MESH:D003389), Anterior uveitis (MESH:D014606), choroidopathies (MESH:D000080363), ischemia (MESH:D007511), retinal detachment (MESH:D012163), orbital cellulitis (MESH:D054517), dendritic keratitis (MESH:D007635), III/IV/VI palsies (MESH:D020434), HZO (MESH:D006563), pain (MESH:D010146), corneal disease (MESH:D003316), Neuro-ophthalmic disease (MESH:C535922), visual decline (MESH:D014786), Muscle (MESH:D019042), afferent pupillary defect (MESH:D011681), Apex Syndromes (MESH:D013577), vascular occlusion (MESH:D008641), skin eruption (MESH:D012871), occlusive vasculitis (MESH:D014657), optic nerve swelling (MESH:D000080344), ophthalmoplegia (MESH:D009886), optic disc edema (MESH:D010211), injury to (MESH:D014947), disease (MESH:D004194), Neurotrophic and (MESH:D009133), Conjunctival inflammation (MESH:D007249), complications (MESH:D008107), Optic nerve diseases (MESH:D009901), Posterior uveitis (MESH:D015866), chickenpox (MESH:D002644), Disciform edema (MESH:D004487), neurologic and ocular complications (MESH:D002493), meningitis (MESH:D008580), Episcleritis (MESH:D015423), epithelial abnormalities (MESH:D002277), ARN (MESH:D015882), vasculopathy (MESH:D000090122), ischemic (MESH:D002545), sensory dysfunction (MESH:D012678), Neuro-Ophthalmic and Orbital Complications (MESH:D009916), Glaucoma (MESH:D005901), iris atrophy (MESH:D007499), Retinal and Choroidal Vasculopathy (MESH:D012164), corneal involvement (MESH:C537363)
- **Chemicals:** famciclovir (MESH:D000077595), Valacyclovir (MESH:D000077483), Acyclovir (MESH:D000212), steroid (MESH:D013256), AS01B (-), Fluorescein (MESH:D019793)
- **Species:** Human alphaherpesvirus 3 (Varicella-zoster virus, no rank) [taxon 10335], Human alphaherpesvirus 1 (Herpes simplex virus type 1, no rank) [taxon 10298], Human alphaherpesvirus 2 (no rank) [taxon 10310], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12942910/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12942910/full.md

## References

123 references — full list in the complete paper: https://tomesphere.com/paper/PMC12942910/full.md

---
Source: https://tomesphere.com/paper/PMC12942910